Dr. Sandler Discusses the Tivantinib Mechanism of Action


Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action

Alan Sandler, MD, division chief of Hematology and Medical Oncology at Oregon Health & Science University, discusses the mechanism of action for tivantinib (formally ARQ 197), an oral, small molecule, c-Met inhibitor currently being investigated in several trials, including MARQUEE, a phase III trial for patients with advanced, non-squamous, non-small cell lung cancer.

Sandler explains that the overexpression of the c-Met protein is associated with malignant tumor growth and has been linked to increased proliferation, invasion, metastasis, tumor angiogenesis and decreased tumor apoptosis. Additionally, the overexpression of c-Met has been implicated in the malignant growth of multiple tumors, making it an important anticancer target.

The agent tivantinib is thought to prevent the downstream effects of c-Met overexpression, by binding to the c-Met receptor, which disrupts the c-Met signal transduction pathways.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine